IQVIA Holdings Inc. (NYSE: IQV), a global provider of advanced analytics solutions and clinical research services to the life sciences industry, reported financial results for the second quarter of 2024.
Second-quarter revenue increased to $3.81 billion from $3.73 billion in the prior-year periodNet Income was $363 million or $1.97 per share in Q2, compared to $297 million or $1.59 per share a year earlierAdjusted earnings increased to $2.64 per share during the three months from $2.43 per share in Q2 2023R&D Solutions’ quarterly bookings were $2.7 billion in Q2, representing a book-to-bill ratio of 1.27xQ2 R&D Solutions contracted backlog was $30.6 billion, up 7.7% reported and 8.1% at constant currency year-over-yearThe company expects full-year 2024 revenue to be between $15.43 billion and $15.53 billionThe adjusted EBITDA guidance for fiscal 2024 is in the range of $3.71 billion to $3.77 billionIt is looking for full-year adjusted earnings per share between $11.10 and $11.30
The post Earnings Summary: IQVIA reports higher revenue and adj. profit for Q2 2024 first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
